Since there is no BCRP/ABCG2 inhibitor approved for clinical use due to the severe side effects on normal cells to date, the combination therapy of gefitinib and sorafenib accordingly seems to be a potential strategy for treatment of advanced HCC. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.